Lecap Asset Management Ltd. lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 68.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,842 shares of the medical research company's stock after selling 27,295 shares during the period. Lecap Asset Management Ltd.'s holdings in Edwards Lifesciences were worth $1,004,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its position in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $1,760,000. Czech National Bank boosted its position in shares of Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock worth $11,214,000 after buying an additional 7,917 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares during the period. Finally, Dynamic Advisor Solutions LLC boosted its position in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after buying an additional 370 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.
Edwards Lifesciences Price Performance
NYSE EW opened at $76.66 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The stock's 50-day moving average is $78.55 and its two-hundred day moving average is $75.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market cap of $45.01 billion, a P/E ratio of 11.03, a price-to-earnings-growth ratio of 3.67 and a beta of 1.05.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $0.70 earnings per share. The business's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts have recently commented on the company. Royal Bank Of Canada raised their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft lifted their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Finally, Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $86.61.
Check Out Our Latest Stock Report on Edwards Lifesciences
Insider Activity
In other news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.
About Edwards Lifesciences
(
Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
